We evaluated a new therapeutic strategy for malignant glioma, which combines intratumoral inoculation of mesenchymal stem cells (MSCs) expressing cytosine deaminase gene with 5-fluorocytosine (5-FC) administration. For in vitro and in vivo experiments, MSCs were transfected with adenovirus carrying either enhanced green fluorescent protein gene (AdexCAEGFP) or cytosine deaminase gene (AdexCACD), to establish MSC-expressing EGFP (MSC-EGFP) or CD (MSC-CD). Co-culture of 9L glioma cells with MSC-CD in a medium containing 5-FC resulted in a remarkable reduction in 9L cell viability. The migratory ability of MSC-EGFP toward 9L cells was demonstrated by double-chamber assay. For the in vivo study, rats harboring 9L brain tumors were inoculated with MSC-EGFP or MSC-CD. Immunohistochemistry of rat brain tumors inoculated with MSC-EGFP showed intratumoral distribution of MSC-EGFP. Survival analysis of rats bearing 9L gliomas treated with intratumoral MSC-CD and intraperitoneal 5-FC resulted in significant prolongation of survival compared with control animals. In conclusion, molecular therapy combining suicide gene therapy and MSCs as a targeting vehicle represents a potential new therapeutic approach for malignant glioma, both with respect to the antitumor potential of this system and its neuroprotective effect on normal brain tissue.
INTRODUCTION
Although conventional therapies for malignant glioma such as surgical resection, radiotherapy and chemotherapy are available, the prognosis for patients with this disease remains extremely poor. 1 This can be traced back to the finding that malignant gliomas have the distinct ability to infiltrate the brain parenchyma and disrupt the neural extracellular matrix. Thus, traces of the primary lesion frequently remain at the borders of the postoperative tumor cavity, eventually leading to tumor recurrence following initial treatment. Therefore, effective new therapeutic tools that specifically target the tumor cells, especially those cells that have escaped the main tumor mass are urgently needed. 2 Current studies suggest that stem cells are effective delivery vehicles for gene therapy against malignant glioma.
3--5 Work by Aboody et al. 3 demonstrated that after intracranial injection, neural stem cells possess wide-ranging tropism for implanted glioma cells and show significant migratory behavior. Furthermore, Ehtesham et al. 5 demonstrated that intracranial injection of neural stem cells engineered to express interleukin-12 (IL-12) or tumor necrosis factor-related apoptosis-inducing ligand exhibited strong antitumor effects in experimental glioma models. However, isolation of the required amounts of autologous or allogeneic neural stem cells for clinical application is limited by technical barriers, ethical uncertainties and by issues with immunologic incompatibility.
Recently, bone marrow stem cells, in particular mesenchymal stem cells (MSCs) have received much attention as an alternative source of neural progenitor cells for clinical application. MSCs, which exist primarily in the bone marrow, can differentiate into osteoblasts, chondrocytes, adipocytes and hepatocytes. 6, 7 Furthermore, in a rat cerebral ischemia model, MSCs have the ability to infiltrate from the initial intracranial injection site to the ischemic lesion. 8, 9 Recently, it was reported that MSCs can migrate toward malignant glioma cells and that gene-transferred MSCs have the ability improve the survival of glioma-bearing mice. 10, 11 These findings suggest that MSCs could act as surrogate neural stem cells and provide the vehicle for molecular therapy against glioma. Furthermore, the in vitro propagation of autologous MSCs for clinical use and implantation into patients with malignant glioma is not associated with the previously identified immunologic and ethical problems.
The 5-fluorocytosine (5-FC)/Escherichia coli cytosine deaminase (CD) system is a suicide gene therapy system that is currently used for malignant tumors. 12, 13 Expression of the CD gene within the target cell produces an enzyme that converts the prodrug, 5-FC, to the toxic metabolite, 5-fluorouracil (5-FU). The use of 5-FC may be particularly suitable for brain tumors, because it can readily cross the blood--brain barrier. As 5-FU is inhibitor of RNA synthesis, it is not toxic to nondividing normal neuronal cells. Moreover, gene therapy with 5-FC/CD also possesses a strong bystander effect that does not require direct cell-to-cell contact. 13 In a recent study of mice bearing melanoma, it was reported that human MSCs expressing CD were associated with tumor regression.
14 Thus, in this study, we sought to evaluate the migratory ability of MSCs and the antitumor effects of 5-FC/CD gene therapy with MSC (5-FC/MSC-CD) as the targeting vehicle in vitro and in vivo models of glioma.
MATERIALS AND METHODS

Cell lines
The 9L rat glioma cells and 293 cells (transformed human embryonic kidney cells) (JCRB9068, Health Science Research Resources Bank, Osaka, Japan) were maintained in Dulbecco's modified Eagle's medium, supplemented with 10% heat-inactivated fetal bovine serum, 100 mg of streptomycin and 100 U of penicillin. The 9L-DsR cells (9L cells labeled with Discosoma red fluorescent protein: DsRed2) were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 800 mg ml --1 G418. The cells were maintained at 37 1C in a humidified atmosphere of 5% CO 2 .
Preparation of MSCs
The MSCs were prepared from rat bone marrow as described previously. 11 Briefly, 6-week-old male Fischer-344 rats (Clea Japan, Fuji, Shizuoka, Japan) were euthanized with ketamine hydrochloride. The femurs and tibias were dissected free of soft tissue and the epiphyses were removed with scissors and the midshaft bone marrow tissue was flushed out into culture medium (Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 100 U of penicillin and 100 mg of streptomycin). A single-cell suspension was obtained by drawing the marrow into syringes through needles of sequentially decreasing size (18, 20 and 22 gauge, respectively) . The MSC primary cultures were seeded at a density of 5 Â 10 7 cells/10-cm dish. To remove the non-adherent cells, the medium was replaced with fresh medium 4 days after initial culture. The MSCs were maintained at 37 1C in 5% CO 2 by exchanging the spent medium with fresh medium at 4-day intervals.
Preparation of recombinant adenovirus vectors and ex vivo gene transduction
Two recombinant replication-deficient adenovirus vectors, AdexCAEGFP (containing the gene for enhanced green fluorescent protein, EGFP) and AdexCACD (containing the CD gene) were constructed from a serotype-5 wild-type adenovirus (Ad5) by inserting the chicken alphaglobin promoter driving the E. coli EGFP gene or the E. coli CD gene into the E1 region of the genome. The E3 region of the adenovirus was deleted. The recombinant adenovirus vectors AdexCAEGFP and AdexCACD were prepared according to previously described methodology. 13 The viral stocks were produced by infecting 293 cells with recombinant adenoviruses, purifying using CsCl density-gradient centrifugation and dialysis against phosphate-buffered saline (PBS) containing 10% glycerol. The stocks were stored at --80 1C. The viral titers were determined with an endpoint cytopathic effect assay on 293 cells and expressed as plaque-forming units (PFUs) per milliliter. Purification of the AdexCAEGFP and AdexCACD viruses yielded concentrations of 1.0 Â 10 10 and 2.6 Â 10 10 PFU ml
, respectively. Ex vivo adenoviral gene transduction of primary MSCs was performed as described previously. 11 Briefly, 1 Â 10 6 MSCs were plated in 10-cm dishes 1 day before adenoviral infection. The cells were infected by incubation with 3 ml of stocked viral solution containing either 1000 PFU per cells of AdexCAEGFP or 20 PFU per cells of AdexCACD at 37 1C in 5% CO 2 for 8 h. For the first 3 h of the infection, the cells were shaken every half hour. At 8 h after infection, the cells were supplemented with 7 ml of normal medium and 48 h after infection, the infected MSCs (MSC-CD, MSC-EGFP) were used for the experiments.
CD enzyme activity assay ) (Kyowa Yakuhin, Wakayama, Japan) was added and maintained at 37 1C in 5% CO 2 . After 24 h of incubation, the supernatant was collected and its 5-FU concentration was measured by highperformance liquid chromatography. 
In vitro cell migration assay
The cell migration assay was performed in double-chamber culture dishes (BD FALCON). The MSC-EGFP cells (5.0 Â 10 4 ) were placed in the upper chamber with 8-mm pores, and the 9L cells (0, 2.5 Â 10 4 and 2.5 Â 10 5 cells) were placed in the lower well. The cell-culture inserts were placed at 37 1C, 5% CO 2 for 24 h, then the number of MSC-EGFPs in the lower side in one high-power field by fluorescent microscopy were directly measured ( Â 40 magnification; Olympus; Tokyo, Japan). 11 Each experiment was done in triplicate.
Intracerebral distribution of implanted MSCs
To evaluate the intracerebral distribution of the MSCs, rats harboring 9L-DsR brain tumors were used for the experiment. Experimental animals were housed and handled in accordance with Okayama University Animal Research Committee guidelines. To establish the brain tumor model, 6-week old male Fisher-344 rats (Clea Japan) (n ¼ 3) were anesthetized with intraperitoneal (i.p.) nembutal (30 mg kg --1 ) and placed in a stereotactic apparatus (Narishige, Tokyo, Japan). The 9L-DsR cells (5 Â 10 5 cells/5 ml) were slowly injected into the basal ganglia of the right cerebral hemisphere (3 mm lateral to the midline, 1 mm posterior to the coronal suture, 4 mm deep from the dura) with a Hamilton syringe (Hamilton, Reno, NV), according to previously published procedures. 13 Seven days after tumor inoculation, rats bearing brain tumors were re-anesthetized and received an intratumoral injection of MSC-EGFP (1 Â 10 6 cells/5 ml) or PBS only (control; 5 ml) according to the same stereotactic coordinates. At 14 days after tumor inoculation, the rats were perfused with PBS and 4% paraformaldehyde while under deep anesthesia. The excised brains were postfixed with 4% paraformaldehyde overnight and then equilibrated in PBS containing 30% sucrose for 48 h. The fixed brains were embedded in OTC (Sakura Fintek USA, Torrance, CA), snap frozen in liquid nitrogen and stored at --70 1C. The tissues were cryosectioned at 18-mm thickness and stained with hematoxylin and eosin or with an anti-GFP monoclonal antibody (Medical and Biological Laboratories, Nagoya, Japan). The sections stained with the first antibody were visualized with a Vectastain kit obtained from Vector Laboratories (Burlingame, CA). The images were acquired with a fluorescent microscope (Biorevo BZ-9000, Keyence, Osaka, Japan).
The antitumor effect of the 5-FC/MSC-CD system in vivo
To assess the antitumor effect of the 5FC/MSC-CD system in vivo, 5.0 Â 10 5 9L cells mixed with an equal quantity of MSC-CD cells or MSC-EGFP cells (control) were implanted subcutaneously into the right flanks of 6-to 8-week-old nude mice (balb/c-nu/nu, CLEA Japan, Tokyo, Japan). The mice had a median weight of 20 g. The mice were treated i.p. with 5-FC (500 mg kg --1 ) or PBS (control) 48 h after tumor implantation. This treatment was repeated once a day for 2 weeks. Tumor length, height and width were measured two times per week with calipers by a researcher blinded to each animal's treatment group.
We also evaluated the antitumor effect of MSC-CD in rats harboring 9L brain tumors. To establish the brain tumor model, the 9L-DsR cells (5 Â 10 5 cells/5 ml) were slowly injected into the right basal ganglia (3 mm lateral to the midline, 1 mm posterior to the coronal suture, 4 mm deep from the dura) of Fisher-344 rats. Five days after tumor inoculation, rats bearing brain tumors were re-anesthetized and received an intratumoral injection of MSC-CD or MSC-EGFP (1 Â 10 6 cells/5 ml) or PBS only (control; 5 ml) according to the same stereotactic coordinates. Treatment with i.p. 5-FC (500 mg kg --1 ) or PBS (control) was commenced 48 h after injection of the MSC and repeated once a day for 2 weeks. The animals were monitored and killed near death, and survival analysis was conducted.
Statistical analysis
The data are expressed as the mean±s.d. The chemosensitivity, in vitro migration ability and the size of flank tumor in each group was compared using a one-way analysis of variance followed by a Scheffé 's post hoc test. Kaplan--Meier curves were compared using the log-rank test. All statistical tests were two-sided. A P-value of o0.05 was considered significant. All statistical analyses were performed with the use of SPSS statistical software (version 14.0; SPSS, Chicago, IL). Figure 2 , the proliferation of 9L-DsR cells was significantly inhibited by co-culture with only 10% MSC-CD in the medium containing 5-FC relative to the control medium. Next, to confirm that the bystander effect did not require cell-to-cell contact, a chemosensitivity assay was performed using double-chamber dish. The MSCs were infected with AdexCACD at an MOI of 0--50 (Figure 3) . A marked, dose-dependent suppression of 9L-DsR cell growth in the medium with 5-FC was observed, regardless of the MOI (10, 20 and 50). There was no statistical difference in growth suppression between either MOI at any concentrations of 5-FC. (Figures 4a and b) .
RESULTS
CD enzyme activity
Migratory ability of MSCs in vitro
Intracerebral distribution and tumor tropism of implanted MSC After the confirmation of the in vitro migratory ability of MSCs, we investigated whether implanted MSCs could migrate toward an intracranial glioma in vivo. The 9L-DsR glioma cells were inoculated into the right basal ganglia, and the MSC-EGFP were injected directly into the glioma 7 days later. The rats (n ¼ 3) were killed 14 days after tumor inoculation and the brain sections were prepared. The EGFP-labeled MSCs infiltrated into the established tumor in a relatively uniform manner (Figure 5a) . Moreover, the GFP-labeled MSCs were densely localized at the border between the tumor and normal parenchyma. By fluorescent microscopy, the GFP-labeled MSCs, most of which retained their spindle-like shape, infiltrated into the DsRed-labeled 9L tumor (Figure 5b ). In addition, the MSCs were observed around the glioma cells, which spread out from the main tumor (Figure 5c ). By fluorescent microscopy, no GFP-positive MSC was observed in distal brain parenchyma where no DsRed-labeled 9L tumor cell invaded. Similar distribution of MSC was observed in all animals. Thus, the MSCs demonstrated significant migratory capability and glioma tropism in the established in vivo tumor model. 
In vivo
DISCUSSION
Glioma tropism of MSC
In this study, we demonstrated that MSCs have the ability to migrate toward glioma cells in vitro and in vivo. Although our study was subjected by using rat MSCs and rat glioma cell line, the migratory activity of MSCs was demonstrated in human cell lines similarly. Park et al. 15 reported that human umbilical cord bloodderived MSCs were able to migrate toward the human glioma cell lines (U-87MG, U-251MG, three primary glioma cell lines). These results suggested that soluble factors released from 9L glioma cells were responsible for the tropism of the MSCs for the glioma cells. This is in agreement with previous reports, which suggest that soluble factors, or chemoattractants, may include various chemokines, cytokines and growth factors. For example, plateletderived growth factor-BB, epidermal growth factor and vascular endothelial growth factor-A have all been shown to enhance tumor tropism of MSCs. 10, 16 Birnbaum et al. 17 reported that the tumor tropism of MSCs is dependent on IL-8, transforming growth factor-b1 and neurotropin-3. In comparison, Xu et al. 18 reported that monocyte chemoattractant protein-1 and stromal cell-derived factor-1a have a role in migration of MSCs toward gliomas. Furthermore, Park et al. 15 reported that overexpression of the stromal cell-derived factor-1a receptor, CXCR4, on human umbilical cord blood-derived MSCs enhanced the migratory capacity of MSCs toward gliomas. In addition, it has been suggested that MSC migration requires extracellular matrix as the toehold. To this end, Schichor et al. 16 reported that laminin and tenascin were involved in MSC migration. In fact, it has been reported that laminin, tenascin, fibronectin, vitronectin and different types of collagen are upregulated within the glioma stroma and at the advancing edge of the tumor within the brain parenchyma. 19, 20 Advantages of MSCs as a glioma-targeting vehicle Despite the genetic heterogeneity of malignant gliomas, common aberrations in the signaling elements involved in their angiogenesis and invasion pathways are known to exist. 21 Although anti-vascular endothelial growth factor therapy (for example, bevacizumab) seems to be effective in normalizing abnormal tumor vasculature, leading to an enhanced response to radiation and chemotherapy, tumors eventually become resistant to the therapy and adopt a highly infiltrative and invasive phenotype. Therefore, it is important to develop a therapeutic option with the ability to track the tumor cells and coupled with one that has multiple mechanisms through which the antitumor activity can occur. There are several advantages of MSCs as a targeting vehicle for malignant glioma. As shown by our experiments, MSCs show active in situ targeting capabilities toward invading glioma cells, whereas conventional antitumor agents including chemotherapeutic drugs and viral vectors have only passive distributive effects after administration. Findings by Nakamura et al. 11 showed the intracranial distribution of MSCs resembled capsule-like structures around the tumor mass. This unique intracranial distribution of MSCs might act as a barrier preventing the spread of glioma cells into the normal parenchyma. Recently, findings suggest that MSCs secrete large amounts of angiogenic factor angiopoietin-1 (Ang1). 22 Coupled to this is the knowledge that angiopoietin-1 can inhibit tumor-vascular leakage and also tumor growth in vivo. Therefore, angiopoietin-1 released from MSCs could represent an additional antitumor effect of MSC. Moreover, other neurotrophic factors are released from MSCs, including nerve growth factor, 23 which can induce the differentiation and the growth inhibition of C6 glioma cells in vitro. This may act as a potential mechanism underlying the antitumor effect exerted by MSCs. 24 In the cerebral infarction model, it has been reported that implanted MSCs mediate neural protection through the inhibition of neuronal apoptosis and this protective effect is thought to be because neurotrophic factors such as nerve growth factor, are released from the MSCs. 23 Therefore, the implantation of MSCs for the treatment of gliomas might be beneficial both with respect to its antitumor potential and its protective effect on normal brain tissues. secretion of a desired therapeutic factor, have the ability to improve the migratory efficiency to specific tumor cells and enhance the antitumor effect of MSCs. Nakamura et al.
11 reported antitumor effect of genetically engineered MSC-expressing human IL-2. Their findings showed prolonged survival in rats bearing 9L brain tumors when treated with MSCs expressing IL-2 compared with those treated with unmodified MSCs. Therefore in this study, IL-2 gene modification of MSCs conferred additional therapeutic benefits. Chen et al. 25 transduced MSCs with an adenovirus engineered to secrete IL-12. Human MSCs, engineered to express interferon-b, have been used for targeted delivery of interferon-b, a potent antiproliferative and proapoptotic agent, in both metastatic 26 and gliomas 10 models. Studies have also shown the antiproliferative, antitumor and immunomodulatory effects of interferon-a, 27 a multifunctional regulatory cytokine. Mohr et al.
28
reported the ability of an adenoviral vector expressing tumor necrosis factor-related apoptosis-inducing ligand to transduce MSCs and the subsequent therapeutic efficacy of these MSCs in a lung cancer model. The potential of mesenchymal progenitor cells to assist the delivery of an oncolytic virus, which targets virus-mediated lysis of tumor cells has been evaluated and may be a novel approach for human glioma therapy.
29--32
Suicide gene-transferred MSC for malignant glioma In our therapeutic system, the 5-FC/CD suicide gene therapy was found to exert its antitumor effect mainly via a bystander effect. The CD gene-transferred MSCs navigated to the glioma cells among the normal brain parenchyma, and the conversion of 5-FC into 5-FU by the CD gene in the vicinity of the migrated glioma cells can impair these single tumor cells. The strong bystander effect of the 5FC/MSC-CD system means that tumor regression is possible using nontoxic levels of 5-FC, even if only a small percentage of MSCs expresses CD. Amano et al. 33 reported that ganciclovir/herpes simplex virus thymidine kinase gene therapy combined with MSCs was effective in the treatment of rat glioma. In that system, however, the bystander effect of ganciclovir/herpes simplex virus thymidine kinase gene therapy required direct cellto-cell contact and was depended on the formation of gap junctions between contact cells and on the expression of connexin-43 in the cells. 34 In contrast, the bystander effect of 5-FC/CD gene therapy does not require direct cell-to-cell contact. 10, 13 Therefore, invasive glioma cells may become extensively disordered if MSCs reach the vicinity of tumor cell.
Future perspectives Although treatment with the 5-FC/MSC-CD system was shown to be effective for the highly invasive malignant glioma, hurdles must be overcome before this therapeutic system could be implemented. First, the experiments conducted in this study were performed in a small animal model. Nevertheless, the capacity of MSCs to migrate through the brain parenchyma suggests that these cells can survive within the central nervous system for a prolonged period of time, a prerequisite condition for use of human MSCs within the much larger human brain. Primate study is desirable before clinical application. Second, the available volume of autologous MSCs is limited. Although our studies have focused on bone marrow-derived MSCs, recent work suggests that other cells in the bone marrow, such as the marrow-derived neural-competent cell, may also be a useful delivery vehicle for brain tumors. 35 Third, preclinical data and the results of early patient trials with cell-based gene therapy suggest that the generation of secondary malignancies is a potential risk. 36, 37 In our system, tumorigenic transformation of MSCs may be avoided because the MSCs themselves, in theory, are killed by the 5-FU.
Conclusions
In this study, we demonstrated the tumor-homing capabilities and antitumor effects of the 5-FC/MSC-CD system in vitro and in vivo. This system demonstrated a potent bystander effect with the ability to kill tumor cells even when the MSCs and tumor cells were not in direct contact leading to the invading glioma cells becoming extensively disordered. This system may represent a promising new therapeutic approach for highly invasive malignant glioma.
